Cerio Jeffrey 4

What Happened
Jeffrey Cerio, General Counsel of Korro Bio, received an option award to acquire 23,000 shares on February 2, 2026. The Form 4 reports the acquisition as 23,000 derivative shares at $0.00 (no cash paid at grant). This is an equity compensation award (not a market purchase or sale).

Key Details

• Transaction date: 2026-02-02; Form 4 filed: 2026-02-03 (timely filing).
• Reported transaction: Grant/award (derivative) of 23,000 shares at $0.00.
• Shares owned after transaction: Not specified in the excerpted filing.
• Footnote: The option vests in 48 equal monthly installments beginning February 2, 2026, subject to continued service.
• No 10b5-1 plan, tax‑withholding sale, or late‑filing indication noted in this filing.

Context
This was an option/award grant, not an immediate exercise or open‑market purchase. The award vests gradually (monthly over four years) and therefore does not represent immediately transferable shares until vesting (and any exercise requirements are met). The filing reports $0 cash paid at grant; the Form 4 excerpt does not disclose an exercise price or intrinsic value.